皮下投与の新型単分子GLP-1およびアミリン受容体アゴニストであるアミクレチン:1b/ 2a期ランダム化対照試験の結果
Kirsten Dahl1, Søren Toubro2, Sohan Dey3
1Novo Nordisk, Måløv, Denmark.
Lancet (London, England)
|June 23, 2025
まとめ
GLP-1およびアミリン受容体の新しいアゴニストであるアミクレチンは,過体重または肥満の成人に著しい体重減少を示した. 胃腸の副作用は一般的だが,治癒可能であり,有効性に関するさらなる研究を支持した.
科学分野:
- 薬理学と内分泌学
- 代謝 疾患 と 肥満 研究
背景:
- アミクレチンは,GLP- 1とアミリン受容体の両方を標的とする新しい単分子アゴニストです.
- この研究では,過剰体重と肥満の管理におけるアミクレチンの可能性が調査されました.
研究 の 目的:
- 皮下アミクレチンの安全性,耐受性,薬動性,体重の影響を評価する.
- 体重過多または肥満患者の36週間の治療期間におけるアミクレチンの有効性を評価する.
主な方法:
- ランダム化され,プラセボ対照のフェーズ1b/ 2a試験で,過体重または肥満 (BMI 27. 0~39. 9 kg/ m2) の18~55歳の参加者が対象となった.
- 参加者は週に1回,アミクレチンまたはプラセボの皮膚下に注射され,投与量は60mgまで増加しました.
- 主要エンドポイントは治療に起因する有害事象で,次要エンドポイントは体重の変化でした.
主要な成果:
- アミクレチンは,様々な投与量と治療期間においてプラセボと比較して体重を大幅に減少させました (例えば,60 mgでは-24. 3%).
- 最も頻繁に発生した副作用は胃腸疾患で,通常は軽度から中度まで,一時的なものでした.
- 参加者の離脱率は高かったが,中止はしばしば治療に起因する有害事象とは無関係であった.
結論:
- 週に一度,最大60mgの皮下アミクレチンは,他のGLP- 1およびアミリンアゴニストと一致する安全性および耐受性プロファイルを示した.
- 胃腸疾患の発生率が高いにもかかわらず,体重減少のためのアミクレチンのさらなる調査をプロファイルがサポートしています.
- 研究結果は,肥満管理におけるアミクレチンの治療的可能性に関する研究を継続することを奨励しています.
関連する概念動画
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K


